Clovis Oncology, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 413
- Market Cap
- -
- Website
- http://clovisoncology.com
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- Conditions
- Advanced Solid TumorGynecologic Cancer
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04042116
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02630186
- Locations
- 🇺🇸
University of California at Los Angeles, Santa Monica, California, United States
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02580708
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Tennessee Oncology, PLLC - The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Rociletinib (CO-1686) USA Expanded Access Program
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Clovis Oncology, Inc.
- Registration Number
- NCT02547675
- Locations
- 🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Sutter Cancer Institute, Sacramento, California, United States
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT02322281
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Saint Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸University of California at Los Angeles, Santa Monica, California, United States
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
- Conditions
- Estrogen Receptor PositiveTriple NegativeMetastatic Breast CancerHER2 PositiveHER2Breast CancerMBCER
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02202746
- Locations
- 🇺🇸
Arizona Oncology Associates, Sedona, Arizona, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02186301
- Locations
- 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Fort Myers, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT02147990
- Locations
- 🇺🇸
UCLA Medical Center, Alhambra, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Saint Jude Heritage Healthcare, Fullerton, California, United States
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
- Conditions
- Squamous Non-Small Cell Lung CancerSCLCNSCLCNon-Small Cell Lung CancerSmall Cell Lung CancerAdvanced Lung CancerStage IV Lung CancerLung CancerMetastatic Lung Cancer
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02109016
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Associates in Oncology and Hematology, Rockville, Maryland, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
- Conditions
- Solid TumorNon-small-cell Lung CancerLung Cancer
- Interventions
- Drug: CO-1.01 and Cisplatin
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01641575
- Locations
- 🇬🇧
University College London Cancer Institute, London, United Kingdom
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States